Article Sidebar

PDF
Date Published: 22/06/2022
Abstract Views: 166
Views PDF: 113
DOI: https://doi.org/10.51298/vmj.v515i1.2670
Issue
Vol. 515 No. 1 (2022)
Section
Các bài báo
How to Cite
Vĩnh Niên, L. ., & Nguyệt Quỳnh Mai, N. . (2022). INVESTIGATION OF 1,5-ANHYDROGLUCITOL CONCENTRATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Vietnam Medical Journal, 515(1). https://doi.org/10.51298/vmj.v515i1.2670

INVESTIGATION OF 1,5-ANHYDROGLUCITOL CONCENTRATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Lâm Vĩnh Niên1,, Nguyễn Nguyệt Quỳnh Mai1
1 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Background: 1,5-AG is a reflective of short-term blood glucose status that cannot be monitored with the HbA1c test. Objectives: To evaluate changes over time and the role of 1,5-Anhydroglucitol in glycemic control. Methods: Cross-sectional study design compared with the change of 1,5-Anhydroglucitol concentration between 2 groups of patients with diabetes (189) and without diabetes (150). Conducted at the Department of Biochemistry - Military Hospital 175 - Ho Chi Minh City from February 2020 to July 2020. Results: The mean concentration of 1.5-AG of 49 patients enrolled in the prospective study after 2 weeks was 9.4 ± 7.2 μg/ml, significantly higher than the baseline at 3. 8 ± 2.9 μg/ml. This difference is statistically significant (p < 0.001). Thus, after 2 weeks, the concentration of 1.5-AG increased by an average of 5.5 g/ml. The average glucose concentration after 2 weeks of the above group of patients was 8.4 ± 5.1 mmol/l, lower than that of the group of patients. with a baseline of 13.2 ± 8.3 mmol/l, the change in concentration was –4.8 mmol/l. There was a strong negative correlation between the concentration of 1.5-AG and HbA1c (correlation coefficient r = -0.71) (p < 0.001). There was a strong negative correlation between the concentration of 1,5-AG and glucose (correlation coefficient r = -0.62) (p < 0.001). Conclusion: The change, rapid response of 1.5-AG after 2 weeks of treatment shows the short-term glycemic control ability of 1.5-AG compared with other glycemic indices.

Article Details

Keywords

Diabetes, HbA1C, 1,5-Anhydroglucitol

References

1. D. R. Whiting (2011), "IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030", Diabetes Res Clin Pract. 94(3), 311-21.
2. B. I. Freedman (2010), "Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis", Perit Dial Int. 30(1), 72-9.
3. W. J. Kim C. Y. Park (2013), "1,5-Anhydroglucitol in diabetes mellitus", Endocrine. 43(1), 33-40.
4. Y. Wang (2012), "A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China", Diabetes Metab Res Rev. 28(4), 357-62.
5. M. Dworacka H. Winiarska (2005), "The application of plasma 1,5-anhydro-D-glucitol for monitoring type 2 diabetic patients", Dis Markers. 21(3), 127-32.
6. K. M. Dungan (2006), "1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes", Diabetes Care. 29(6), 1214-9.
7. C. Ma (2017), "Excretion rates of 1,5-anhydro-D-glucitol, uric acid and microalbuminuria as glycemic control indexes in patients with type 2 diabetes", Sci Rep. 7, 44291.
8. J. B. McGill (2004), "Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay", Diabetes Care. 27(8), 1859-65.